熱門資訊> 正文
InMed Pharmaceuticals GAAP每股收益为-0.73美元
2026-05-07 06:08
- InMed Pharmaceuticals press release (INM): Q3 GAAP EPS of -$0.73.
- As of March 31, 2026, the Company's cash, cash equivalents and short-term investments were $5.2 million, which compares to $10.8 million on June 30, 2025.
More on InMed Pharmaceuticals
- InMed Pharma gets Nasdaq non-compliance notice
- Financial information for InMed Pharmaceuticals
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。